Hasil Pencarian - L. Pour

  • Menampilkan 1 - 9 hasil dari 9
Perbaiki Hasil
  1. 1
    Investigation into the Role of Information and Communication Technology at University's Education

    Investigation into the Role of Information and Communication Technology at University's Education oleh L. Pour Mohammad Baqer, E. Pour Mohammad Baqer

    Diterbitkan 2008-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Total phenolics, flavonoids content and antioxidant capacities of grape pomace fermented by Aspergillusoryzae

    Total phenolics, flavonoids content and antioxidant capacities of grape pomace fermented by Aspergillusoryzae oleh R Ashrafi Yorghanloo, M Alizadeh Khaledabad, M Rezazad Bari, L Pour Akbar

    Diterbitkan 2015-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    PB1974: MULTIVARIATE SPECTRAL BIOTYPING OF EXTRAMEDULLARY MULTIPLE MYELOMA

    PB1974: MULTIVARIATE SPECTRAL BIOTYPING OF EXTRAMEDULLARY MULTIPLE MYELOMA oleh M. Vlachová, J. Gregorová, S. Adamová, L. Pečinka, L. Moráň, V. Porokh, M. Štork, L. Pour, J. Havel, P. Vaňhara, S. Ševčíková

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS

    ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS oleh A Maiolino, R Hajek, T Jelinek, P Moreau, T Martin, L Pour, G Mikala, A Symeonidis, S Bringhen, A Rawlings, ML Risse, H Vande-Velde, I Spicka

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001

    EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARIS... oleh X. Leleu, M. Beksac, T. Chou, M.A. Dimopoulos, S. Yoon, H.M. Prince, A. Chari, A. Oriol, D.S.D. Siegel, M. Khurana, M. Qi, M. Obreja, L. Pour, T. Shelekhova

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI

    P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG... oleh M Mateos, M Szarejko, J Bila, F Schjesvold, I Spicka, V Maisnar, A Jurczyszyn, Z Grudeva-Popova, R Hajek, G Usenko, M Thuresson, S Norin, S Jarefors, P Richardson, L Pour

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE

    P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE oleh M. Vlachová, M. Štork, S. Ševčíková, T. Jelínek, J. Minařík, J. Radocha, P. Krhovská, L. Pospíšilová, I. Špička, J. Straub, P. Pavlíček, A. Jungová, V. Sandecká, V. Maisnar, R. Hájek, L. Pour

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS

    B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS oleh P. Musto, M.C. Minnema, W.W.H. Roeloffzen, A. Capra, B. van der Holt, A. Juul Vangsted, A. Broyl, F. Schjesvold, T. Lund, T. Silkjaer, R. Benjamin, M. Grasso, K. Lung Wu, J. Caers, M. Cavo, R. Hájek, B. Bruno, A. Gadisseur, G. Pietrantuono, M. Offidani, L. Pour, P. Sonneveld, M. Boccadoro, N. van de Donk

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS

    B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR... oleh N. van de Donk, M.C. Minnema, B. van der Holt, F. Schjesvold, K.L. Wu, A. Capra, A. Broyl, W.W.H. Roeloffzen, A.P.A. Gadisseur, G. Pietrantuono, L. Pour, V. van der Velden, T. Lund, M. Offidani, M. Grasso, L. Giaccone, M. Cavo, T. Silkjaer, J. Caers, S. Zweegman, R. Hajek, R. Benjamin, A. Vangsted, M. Boccadoro, F. Gay, P. Sonneveld, P. Musto

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: